CA2338283A1 - Ligands multivalents du recepteur de avb3 et des recepteurs associes aux metastases - Google Patents

Ligands multivalents du recepteur de avb3 et des recepteurs associes aux metastases Download PDF

Info

Publication number
CA2338283A1
CA2338283A1 CA002338283A CA2338283A CA2338283A1 CA 2338283 A1 CA2338283 A1 CA 2338283A1 CA 002338283 A CA002338283 A CA 002338283A CA 2338283 A CA2338283 A CA 2338283A CA 2338283 A1 CA2338283 A1 CA 2338283A1
Authority
CA
Canada
Prior art keywords
compound
gly
seq
group
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002338283A
Other languages
English (en)
Inventor
Kam F. Fok
Foe S. Tjoeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2338283A1 publication Critical patent/CA2338283A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention se rapporte à des composés pharmaceutiques qui sont des ligands multivalents du récepteur de a¿v?b¿3? et des récepteurs associés aux métastases. L'invention se rapporte également à l'utilisation de ces ligands multivalents, seuls ou associés à d'autres agents, dans des compositions pharmaceutiques et dans des méthodes de traitement des troubles à médiation assurée par a¿v?b¿3? permettant le traitement du cancer et d'autres maladies angiogéniques, telles que la rétinopathie diabétique, l'arthrite, les hémangiomes et le psoriasis.
CA002338283A 1998-08-13 1999-04-07 Ligands multivalents du recepteur de avb3 et des recepteurs associes aux metastases Abandoned CA2338283A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9644298P 1998-08-13 1998-08-13
US60/096,442 1998-08-13
PCT/US1999/004296 WO2000009143A1 (fr) 1998-08-13 1999-04-07 Ligands multivalents du recepteur de avb3 et des recepteurs associes aux metastases

Publications (1)

Publication Number Publication Date
CA2338283A1 true CA2338283A1 (fr) 2000-02-24

Family

ID=22257375

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002338283A Abandoned CA2338283A1 (fr) 1998-08-13 1999-04-07 Ligands multivalents du recepteur de avb3 et des recepteurs associes aux metastases

Country Status (5)

Country Link
EP (1) EP1104304A1 (fr)
JP (1) JP2002522504A (fr)
AU (1) AU3449899A (fr)
CA (1) CA2338283A1 (fr)
WO (1) WO2000009143A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
WO2009046080A1 (fr) 2007-10-01 2009-04-09 Pharmaessentia Corp. Interféron-alpha modifié n-terminal
US8877158B2 (en) 2009-06-12 2014-11-04 Fujifilm Corporation Targeting agent to newly formed blood vessels
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
US20180201645A1 (en) * 2015-12-21 2018-07-19 Brainon Inc. Composition for improving memory, learning ability, and cognitive ability

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020229A1 (fr) * 1992-04-03 1993-10-14 Genentech, Inc. ANTICORPS DE L'INTEGRINE ALPHA v BETA 3
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
WO1997036858A1 (fr) * 1996-03-29 1997-10-09 G.D. Searle & Co. Derives de l'acide alcanoique de cyclopropyle
JP2002510709A (ja) * 1998-04-08 2002-04-09 ジー・ディー・サール・アンド・カンパニー 二重Ａｖｂ３及び転移関連受容体リガンド

Also Published As

Publication number Publication date
EP1104304A1 (fr) 2001-06-06
WO2000009143A1 (fr) 2000-02-24
JP2002522504A (ja) 2002-07-23
AU3449899A (en) 2000-03-06

Similar Documents

Publication Publication Date Title
TW538048B (en) A soluble derivative of a soluble polypeptide and its use
JP4332163B2 (ja) Ｍｐｌ受容体に結合し血小板生成活性を有する二量体トロンボポエチンペプチド模倣体
EP1705248A1 (fr) Protéines de fusion comprenant une fraction d'angiostatine et leur utilisation dans un traitement ant-tumeur
CZ302303B6 (cs) Homodimerní fúzní protein vykazující inhibicní aktivitu na angiogenezi, zpusob jeho produkce, molekula DNA a replikovatelný expresní vektor
US20060172941A1 (en) Anti-angiogenic peptides and methods of use thereof
KR20220123294A (ko) 폴리펩티드, 이의 제조방법 및 용도
JP2003530070A (ja) Ｆｃ融合タンパク質としてのインターフェロン−αタンパク質の発現および搬出
JPH06509551A (ja) Ｇｐ　ＩＩ↓ｂＩＩＩ↓ａに対する高い特異性を有する血小板凝集阻害剤
WO1990013306A2 (fr) Petits polypeptides
CA2325342A1 (fr) Ligands doubles du recepteur avb3 et du recepteur associe aux metastases
EP2714064B1 (fr) Blocage de protéases inflammatoires par des thêta-défensines
JP2004526416A (ja) 抗血管新生性ポリペプチド及び血管新生を抑制するための方法
CA2355874A1 (fr) Inhibiteurs de l'integrine $g(a)v$g(b)6
JP2007506795A (ja) ボツリヌス菌ｃ３エキソトランスフェラーゼ組成物及び腫瘍の拡大を治療するための方法
US8455447B2 (en) Modified therapeutic agents
CA2338283A1 (fr) Ligands multivalents du recepteur de avb3 et des recepteurs associes aux metastases
JPH06509116A (ja) 修正されたｐｆ４組成物及び使用方法
CA2333929A1 (fr) Derives de polypeptides
JP2008532505A (ja) 二量体または多量体のマイクロタンパク質
AU781134B2 (en) Methods for treating tumors using antiangiogenic compounds
US20040052810A1 (en) Abrogen polypeptides, nucleic acids encoding them and methods for using them to inhibit angiogenesis
EP1041999A1 (fr) Chimeres et conjugues polypeptidiques thrombogenes presentant une activite dependant de l'association avec l'endothelium vasculaire tumoral
MXPA01006229A (en) &agr;v

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20060407